Thyrocare Technologies reported a strong fiscal performance for the quarter ended March 31, 2026. The company achieved a 20% year-on-year revenue growth to INR 223.95 crore, while Profit After Tax (PAT) surged by 128% to INR 48.70 crore. This growth was driven by a robust performance in the pathology segment and sustained operational efficiency, positioning the company for continued success in the diagnostic industry.
Financial Performance Overview
Thyrocare Technologies demonstrated significant financial momentum in Q4FY26. Consolidated revenue rose to INR 223.95 crore, marking a 20% growth compared to the same period in the previous year. This performance was supported by a 31% year-on-year increase in EBITDA, which reached INR 75.09 crore. The company’s bottom line saw substantial improvement, with PAT climbing 128% year-on-year to INR 48.70 crore, reflecting a strong focus on profitable operations.
Annual Results and Operational Highlights
For the full Financial Year 2026, Thyrocare reported a consolidated revenue of INR 829.04 crore, representing a 21% year-on-year increase. Annual PAT grew by 81% to INR 162.85 crore. A key driver of this success was the volume of diagnostic tests processed, which reached 209.6 million tests for the year, a 23% increase over the previous year. Thyrocare also maintained its industry-leading position by processing 59.0 million tests in Q4FY26 alone.
Strategic Expansion and Quality Standards
The company continues to diversify its clinical offerings. Notable strategic advancements include the expansion into advanced allergy testing with over 250 SKUs on the Phadia platform and a new foray into the genomics market with the launch of Non-invasive Pre-Natal Testing (NIPT). Furthermore, Thyrocare reaffirmed its commitment to service excellence by achieving Six Sigma quality standards, reducing complaints to 3.1 per million tests—a 34% improvement year-on-year—with an average turnaround time (ATAT) of just 3.43 hours.
Source: BSE
